Patient Statistics

Brain damage often results in visual disturbances. For example, between 20-30% of stroke patients suffer some loss of visual function. This can include visual field loss, double vision and visual neglect. Approximately 13% of stroke patients will suffer from visual field loss as a result of damage to the temporal, parietal or occipital lobes.
 
Neuro-Eye Therapy has been designed for those who have suffered from visual field loss as a result of brain damage caused either by a stroke or other acquired brain injury.

Development of Neuro-Eye Therapy

Neuro-Eye Therapy was researched and developed at the University of Aberdeen. The concept of the therapy stemmed from the realisation that the only options available to patients with vision loss were techniques designed to help with coping with changes to their vision rather than stimulating changes to occur within the visual system.

Professor Sahraie and colleagues demonstrated that through systematic stimulation of blind areas using visual stimuli it is possible to improve visual sensitivity. They have hypothesised that this improvement in visual sensitivity in areas of the blind field can occur via two possible ways. There may be parallel routes for nerves to take visual information to different brain areas, so if one route is damaged then processing by other routes can be encouraged. Alternatively, the brain may be able to be trained to use surviving functioning nerves with the damaged areas. Neuro-Eye therapy was designed by researchers to encourage the use of remaining nerve pathways to compensate for the damaged areas. The therapy ultimately relies on the intrinsic ability that the brain has to adapt to changing circumstances, a process called neuroplasticity.

Sight Science Ltd was formed as a spin out company of the University of Aberdeen following this successful research. Neuro-Eye Therapy was developed under clinical and scientific expertise in the field of vision function following stroke and other acquired brain injuries.